https://www.selleckchem.com/pr....oducts/pembrolizumab
66-0.83, P0.001, I =48.2%) and DFS or RFS (HR =0.71, 95% CI 0.61-0.84, P0.001, I =18.2%). Further subgroup analyses indicated similar results in articles that reported intrapulmonary lymph node dissection (HR =0.67, 95% CI 0.57-0.77, P0.001, I =. The results indicate that the presence of skip metastasis is associated with a marked increase in survival of NSCLC patients compared to patients with non-skip N2 metastasis. These results suggest that skip metastasis might be a distinct subgroup for purposes of N staging of
Aimer
Commentaire
Partagez
